NHS Rare Disease Services and 100,000 Genomes

Overview

A rare disease is defined as one affecting fewer than one in two thousand people. The UK Rare Diseases Framework, published in 2021, sets out the strategy for improving diagnosis, care and research. NHS England commissions Highly Specialised Services for specific ultra-rare conditions, often delivered at a small number of national centres. The Genomic Medicine Service runs the world-leading 100,000 Genomes Project and subsequent expanded genome sequencing programmes. Patient organisations play a substantial role in supporting families.

The diagnostic journey

Rare diseases often present with non-specific symptoms and take years to diagnose. The 'diagnostic odyssey' is well-documented: patients see multiple specialists before the correct diagnosis is reached. Genome sequencing has significantly shortened this for many patients. The NHS Genomic Medicine Service offers whole-genome sequencing for eligible patients with suspected rare genetic conditions; results can identify the underlying condition and guide treatment.

Highly Specialised Services

NHS England commissions Highly Specialised Services (HSS) for around eighty ultra-rare and very rare conditions. HSS centres are usually one or two nationally for each condition, ensuring sufficient expertise and case volume. Examples include severe inherited metabolic conditions, complex paediatric cancers, certain rare blood disorders and complex congenital syndromes. Patients are referred to the centre from their local team.

The Genomic Medicine Service

The Genomic Medicine Service (GMS) provides genetic and genomic testing across the NHS, including whole-genome sequencing where indicated. Seven NHS Genomic Medicine Service Alliances cover England, with two specialist labs. Tests are ordered through clinical genetics services after assessment. Results inform diagnosis, treatment choice and family genetic counselling.

Patient organisations and support

Patient organisations are essential in the rare disease space. They support patients and families through diagnosis, advocate for research and treatment, and host disease-specific networks. Rare Disease UK and Genetic Alliance UK provide umbrella support. Disease-specific charities (Cystic Fibrosis Trust, Huntington's Disease Association, Genetic Disorders UK and many more) host specialist services for individual conditions.

Devolved nation variations: Scotland, Wales, Northern Ireland

NHS arrangements vary across the four UK nations under their respective health and social care frameworks. NHS Scotland operates under the Scottish Government and offers free prescriptions, free dental examinations and somewhat different commissioning arrangements through Health Boards rather than Integrated Care Boards. NHS Wales is the equivalent body in Wales with free prescriptions and integrated public health functions through Public Health Wales.

Health and Social Care Northern Ireland (HSC) is the integrated health and social care provider in Northern Ireland, structured differently from NHS England with combined health and social work commissioning. Prescription charges are free in all three devolved nations. Cross-border patients may move between systems; reciprocal arrangements within the UK mean treatment is generally accessible regardless of which nation issued the patient's NHS number.

Specific service availability, waiting times and commissioning priorities differ between the nations. Patient information is published by NHS Inform (Scotland), NHS 111 Wales and HSC Northern Ireland respectively. Cross-border referrals use established protocols between trusts and Health Boards.

Complaints, advocacy and patient voice

NHS complaints follow the NHS Complaints Regulations 2009. The first step is the provider's own complaints process (most trusts have a complaints team and a Patient Advice and Liaison Service for informal resolution). The trust must acknowledge complaints within three working days and respond substantively within a reasonable period, normally six months.

Unresolved complaints can be escalated to the Parliamentary and Health Service Ombudsman (PHSO), which investigates maladministration in NHS services. Independent advocacy is available free through the Independent NHS Complaints Advocacy Service commissioned by each local authority. Specialist advocacy on clinical negligence is provided by Action Against Medical Accidents (AvMA).

Healthwatch operates at local and national level as the statutory patient voice, gathering feedback and influencing commissioning decisions. The Care Quality Commission (CQC) inspects and rates NHS services from 'Inadequate' to 'Outstanding'; reports are published at cqc.org.uk and offer patient-facing information on service quality. Integrated Care Boards in England commission most NHS services and have public-facing complaints and feedback channels.

Confirming your NHS entitlement on arrival

Most UK residents are entitled to NHS care free at the point of use. The Department of Health and Social Care publishes guidance setting out who is exempt from charges and who is chargeable. Visa holders pay the Immigration Health Surcharge upfront with their visa application and are then entitled to the same NHS access as settled residents for the duration of the visa.

Patients can confirm their NHS number through the NHS App or by phoning the local GP surgery once registered. The NHS number is the identifier across all NHS services including hospitals, dentists, pharmacies and screening programmes. Without an NHS number, services can still treat the patient but record-keeping is harder.

Special groups have specific entitlement protections: asylum seekers and refugees are exempt from hospital charges under the Charges to Overseas Visitors Regulations 2015; victims of modern slavery, looked-after children and certain other groups have specific exemptions. The NHS website nhs.uk/using-the-nhs/about-the-nhs/healthcare-in-england-for-visitors-from-overseas/ sets out the categories.

The diagnostic odyssey and how to shorten it

Rare diseases often present with non-specific symptoms and take years to diagnose. The 'diagnostic odyssey' is well-documented: many patients see five or more specialists across multiple years before receiving the correct diagnosis. Genomics England research has found that whole-genome sequencing can shorten this dramatically for patients with suspected genetic conditions.

The NHS Genomic Medicine Service (GMS) offers whole-genome sequencing for eligible patients with suspected rare genetic conditions through Clinical Genetics services. The GP or specialist refers to clinical genetics, which assesses the family history and clinical features and arranges appropriate genetic testing. Test panels for specific suspected conditions, exome sequencing, or whole-genome sequencing are deployed based on the clinical question.

Patient organisations are an important resource for diagnostic odyssey patients. They can point families to specialist clinics, recommend specific clinicians with expertise in rare conditions, and provide peer support during the often-lengthy diagnostic process. Rare Disease UK and Genetic Alliance UK maintain directories of disease-specific patient organisations.

Highly Specialised Services and where they are based

NHS England commissions Highly Specialised Services (HSS) for around eighty ultra-rare and very rare conditions. The services are concentrated at one or two national centres to ensure sufficient expertise and case volume. Examples include severe inherited metabolic conditions, certain rare paediatric cancers, complex congenital syndromes and rare neurological conditions.

Major HSS centres include Great Ormond Street Hospital (paediatric), University College London Hospitals, Royal Brompton Hospital, Birmingham Children's Hospital, Manchester University NHS Foundation Trust, and several others. The Highly Specialised Services list at england.nhs.uk specifies which conditions are served by which centres. Patients are referred to the appropriate centre from their local team.

Travel and accommodation support for families attending HSS centres is available through specific charities and NHS arrangements. The Healthcare Travel Costs Scheme covers some travel costs for low-income patients; specific rare-disease charities have hardship funds. Hospital trusts running HSS centres often have family accommodation on or near the hospital site.

The Genomic Medicine Service in detail

The Genomic Medicine Service runs through seven NHS Genomic Medicine Service Alliances covering England, with two specialist Genomic Laboratory Hubs. Each Alliance serves a defined geography and works with NHS trusts to deliver genomic testing alongside clinical care. The Test Directory specifies which tests are available for which clinical scenarios.

Tests are ordered through clinical genetics services after assessment. The patient or family member provides a blood sample (or sometimes saliva for some tests). Whole-genome sequencing is sent to the lab; analysis takes weeks to months depending on the test type. Results are returned to the referring clinical genetics team, which discusses with the patient and family. Family-member testing (cascade testing) can identify others at risk who can then access surveillance or preventive treatment.

The 100,000 Genomes Project that initiated the GMS completed in 2018 and pioneered routine whole-genome sequencing in the NHS. Successor programmes including the Generation Study (sequencing newborns to detect genetic conditions before symptoms) continue to expand the service. Research participation alongside clinical testing is offered to many patients.

Treatment access and the regulatory pathways

Rare disease treatments can be extremely expensive; some single-dose gene therapies cost over one million pounds per patient. NICE assesses medicines including those for rare diseases through standard appraisals and through the Highly Specialised Technologies (HST) programme for very rare conditions. The HST programme has different cost-effectiveness thresholds reflecting the unique characteristics of ultra-rare disease.

Where a treatment is licensed but not NICE-recommended, individual funding requests (IFRs) can be made to the Integrated Care Board through the patient's specialist. IFRs require evidence of exceptional clinical circumstances. The Cancer Drugs Fund and the broader Innovative Medicines Fund cover specific treatments awaiting full assessment.

Clinical trials are an important treatment-access route for rare disease. The NIHR Be Part of Research website (bepartofresearch.nihr.ac.uk) lists open trials. Many patient organisations maintain disease-specific trial registries and help patients connect with research teams. Early-phase trials of gene therapies and targeted treatments are increasingly available in UK centres.

How NHS services are commissioned and funded

NHS services in England are commissioned by Integrated Care Boards (ICBs), forty-two regional bodies established in 2022 under the Health and Care Act 2022. Each ICB plans, commissions and pays for NHS services for its population, replacing the previous Clinical Commissioning Groups. Commissioning includes primary care (through the NHS England regional teams in some areas), secondary care from NHS Trusts, community services, mental health services, and continuing healthcare.

Funding flows from the Department of Health and Social Care to NHS England, which allocates to ICBs based on a formula reflecting population size, age structure, deprivation and other factors. ICBs then contract with providers for specific services. The provider mix includes NHS Trusts (the majority of secondary care), GP practices (contracts under the General Medical Services or alternative contracts), independent providers under NHS Standard Contract, and charity-sector providers for some specialised services.

Patient choice operates within the commissioning framework: patients can choose between providers for non-urgent consultant-led care via the e-Referral Service. Specialist services are commissioned at regional or national level for very rare or technically demanding care. Local Authority commissioning covers adult social care, public health functions (smoking cessation, sexual health) and certain children's services.

Quality, safety and patient feedback channels

The Care Quality Commission (CQC) is the independent regulator of all NHS and many independent health and social care services in England. CQC inspections rate services from 'Inadequate' to 'Outstanding' based on five key questions: Are they safe, effective, caring, responsive and well-led? Reports are published at cqc.org.uk and patients can use them when choosing providers.

The National Institute for Health and Care Excellence (NICE) issues guidance on clinical practice, technology appraisals (which drugs and devices the NHS should fund) and quality standards. NICE Technology Appraisal Guidance is mandatory for NHS commissioning in England within ninety days of publication. NICE Clinical Guidelines are advisory but widely followed.

Patient feedback is gathered through the Friends and Family Test (a single-question score at point of care), patient surveys including the National GP Patient Survey published by NHS England, NHS choices/nhs.uk patient reviews, and Healthwatch local and national bodies. Patient feedback informs commissioning decisions, CQC inspection priorities and ongoing improvement at provider level.

Your rights as an NHS patient

The NHS Constitution sets out patient rights under the NHS in England. Key rights include: the right to NHS services free at the point of use except where charges are authorised; the right to access NHS services within maximum waiting times; the right to choice of provider; the right to be involved in decisions about your care; the right to be treated with dignity and respect; the right to confidentiality; the right to access your own health records; the right to complain and have complaints investigated.

Specific waiting-time rights include the eighteen-week right to start consultant-led treatment after referral, the two-week wait for suspected cancer referrals and the four-hour A&E target. These rights are not absolute (the NHS Constitution states they apply 'where clinically appropriate') but are enforceable through complaints and ultimately judicial review in extreme cases. The trust must offer an alternative provider where it cannot meet the eighteen-week target.

Choice rights cover most planned consultant-led care. Patients can choose between providers at the point of GP referral through the NHS e-Referral Service. Choice does not apply to emergency care, mental health detention, or some specialised tertiary services. Patient choice protections are an important lever for those facing long local waits; alternative providers in nearby regions can be accessed under the same NHS terms.

Confidentiality and data rights are governed by the UK GDPR, the Data Protection Act 2018 and NHS-specific guidance. Patients can access their own records through the NHS App or by Subject Access Request. Data sharing for direct care is permitted; secondary uses (research, planning) require either consent or compatibility with the National Data Opt-Out. Specific data flows including the Summary Care Record and Shared Care Record have additional governance.

Provider types: NHS Trusts, Foundation Trusts, private under NHS contract

NHS Trusts deliver hospital and community services. Foundation Trusts have additional autonomy from central government but operate under the same NHS rules. Both are regulated by the Care Quality Commission and NHS England. Each Trust has a chief executive, a board of directors, governors and a clinical leadership team.

Independent (private) sector providers deliver some NHS services under NHS Standard Contract. The arrangement provides NHS-funded care from a private hospital, often for elective surgery to reduce NHS waiting times. The patient experience is NHS-style (NHS funding, NHS waiting-time entitlement) delivered in a private hospital setting. Major independent providers serving NHS patients include Spire, Nuffield Health, Ramsay, Circle and BMI Healthcare in some areas.

Primary care is delivered by GP practices contracted under the General Medical Services contract or Personal Medical Services arrangement. Practices are independent businesses contracted with the NHS, not NHS-owned. Many practices have multiple sites and operate at scale; others are single-site small partnerships. Primary Care Networks (groups of practices serving 30,000 to 50,000 patients) coordinate care across practices and host shared roles including First Contact Physiotherapists and clinical pharmacists.

Community services (district nursing, community physiotherapy, mental health teams, learning disability teams) are commissioned by ICBs and provided by NHS Trusts, social enterprises or charity-sector providers depending on the area. Mental health trusts handle specialist mental health services including inpatient psychiatric care, community mental health teams and specialist services. Ambulance services are provided by ten regional NHS ambulance trusts in England.

NHS technology and digital transformation

NHS digital transformation has accelerated since 2020. The NHS App now covers most major patient touchpoints: appointment booking, prescription ordering, medical record access, NHS 111 online integration. The app is the most widely used UK government-related app and operates under the NHS login security framework. Authentication uses NHS login with identity verification through GOV.UK Verify-style processes.

Electronic Prescription Service routes more than ninety percent of UK prescriptions electronically from prescriber to pharmacy. Patients nominate a pharmacy through the app or the surgery; subsequent prescriptions flow there automatically. The Summary Care Record provides allergies and current medications to clinicians outside the patient's regular practice; the Shared Care Record being rolled out provides the full record across health and social care.

Specialist digital services include the e-Referral Service (specialist appointment booking), the National Care Records Service, the National Cancer Records and the National Diabetes Audit. Behind these patient-facing services sits a complex landscape of clinical systems (SystmOne, EMIS Web in primary care; Cerner, Epic and others in secondary care) that have variable interoperability. NHS England's strategy aims to improve cross-system data flow through APIs and shared standards.

Artificial intelligence and machine learning are being deployed cautiously in NHS settings, primarily in imaging diagnostics (radiology AI for cancer detection), pathology (histology AI), and predictive analytics for service planning. Specific NHS Long Term Plan commitments cover AI adoption with safety and equity safeguards. The MHRA regulates AI as a medical device where it provides clinical decision support.

Disclaimer

This article provides general information for UK residents and newcomers. It is not legal, tax, financial or medical advice. Rules, rates, eligibility criteria and processes change frequently; readers should verify details with the linked primary sources or consult an authorised professional before acting on anything described here. References to specific firms, products or services are illustrative and do not constitute endorsements.

Frequently asked questions

How do I get a genetic diagnosis on the NHS?

Through clinical genetics services. The GP or specialist refers the patient to the regional clinical genetics centre, which assesses the family history and clinical features and arranges appropriate genetic testing. The test type depends on the clinical question: targeted gene panels for specific conditions, exome sequencing for broader investigation, or whole-genome sequencing where indicated. Results often take several months. Family-member testing follows where the genetic cause is identified. Many disease-specific patient organisations advise on which testing route fits which presentation.

What support is available for rare disease patients?

NHS Highly Specialised Services for designated conditions; clinical genetics services for diagnosis; patient organisations for peer support and condition-specific information; the Genetic Counselling service for family planning conversations. Disease-specific charities (Cystic Fibrosis Trust, Huntington's Disease Association, Genetic Disorders UK, Muscular Dystrophy UK, and many more) host specialist services for individual conditions. Rare Disease UK and Genetic Alliance UK provide umbrella support. The Be Part of Research website lists trials seeking participants.

Are rare disease treatments funded by the NHS?

Where licensed and recommended by NICE or the Highly Specialised Technologies programme, yes. Some rare disease treatments are extremely expensive; NICE assesses cost-effectiveness and the HST process applies for ultra-rare conditions with different thresholds reflecting the rarity. Some treatments are accessed through clinical trials. Individual funding requests through the Integrated Care Board apply where a treatment is not routinely commissioned but the patient has exceptional clinical circumstances. The Innovative Medicines Fund covers some treatments awaiting full NICE assessment.

Can I participate in rare disease research?

Yes. The Be Part of Research website (bepartofresearch.nihr.ac.uk) lists eligible trials open to recruitment. Patient-recruitment registries for specific conditions are run by patient organisations and the academic centres conducting the research. Many UK research teams welcome inquiries from patients about whether they fit current trials. The 100,000 Genomes Project and successor programmes include research participation alongside clinical testing for many participants.

Will my genome data be confidential?

Yes. NHS genomic data is held under strict confidentiality and access controls. Research uses are governed by ethics approval and the patient's explicit consent. The National Data Opt-Out applies for secondary uses. The Genomic Medicine Service publishes its data sharing arrangements and patients can ask for full details of who can access their data and for what purpose. Genomics England publishes its information governance frameworks; access to the Genomics England research environment is by approved researcher only, with strict data-handling controls.